Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Avian influenza virus prevention in the domestic host by a deactivated vaccine

Award Number: R21AI194176
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/17/2026
PERIOD OF PERFORMANCE END DATE: 05/31/2028

Group Awards By:

View Award Description

Avian influenza virus prevention in the domestic host by a deactivated vaccine - Abstract Influenza viruses, which affect both birds and mammals, pose a substantial public health concern. An estimated 10% of the global population annually becomes infected, resulting in 300,000 to 600,000 deaths worldwide. Our research objectives are to develop a Hemagglutinin (HA) and Neuraminidase (NA) based rabies-vectored vaccine against highly pathogenic Avian Influenza (HPAI) A virus H5N1. We have already demonstrated the vaccine’s immunogenicity and protective efficacy against HPAI H5N1 Vietnam 1203. To advance this research, we propose to utilize a novel RAVB-based deactivated vaccine that harbors the H5 antigens of the current homologous circulation (clade 2.3.4.4b) and a construct expressing N1. Our first aim will involve comparing the H5 or H5/N1 RABV-based vaccines against challenges by PR8 recombinants carrying H5N1 proteins in mice. We will employ a single immunization and a prime/boost approach, either with or without an adjuvant approved for use in animals and humans (SEPIVAC SWE™). We will assess the role of T cells in the vaccine-induced protection by performing CD4/CD8 depletion before challenge Our second aim will utilize the vaccine approach identified to protect our mouse system in dairy cows. Subsequently, we will assess the vaccine’s efficacy against challenges administered intranasally and intramammary. We will verify the role of the vaccine-induced antibodies in protection against H5N1 by performing passive transfer studies of purified IgG from vaccinated cows before challenge. In summary, this study will evaluate the efficacy and delineate the mechanism of protection of a safe and well- established vaccine platform to protect against HPAI H5 and explore its potential as an animal and human vaccine.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $221,250 )
2026	2026	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	000	1	6/19/2026	NEW	$221,250
														Subtotal = $221,250

Grand Total All Awards = $221,250

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Avian influenza virus prevention in the domestic host by a deactivated vaccine

Award Number: R21AI194176

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/17/2026

PERIOD OF PERFORMANCE END DATE: 05/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer